Cancer biotech Inspirna winding down as its odyssey in microRNA comes to an end
It’s been an inauspicious start to the first quarter as many biotechs are forced to slash and burn. Inspirna is the latest victim of this trend, although it’s going one step further.
It’s been an inauspicious start to the first quarter as many biotechs are forced to slash and burn. Inspirna is the latest victim of this trend, although it’s going one step further.
